Comparative effectiveness clinical trials in psychiatry: Superiority, noninferiority, and the role of active comparators

Journal of Clinical Psychiatry

Volumn 72, Issue 10, 2011, Pages 1344-1349

  Leon, Andrew C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; ILOPERIDONE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PSYCHIATRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SCHIZOPHRENIA; STUDY DESIGN;

EID: 80054890394     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06089whi     Document Type: Article

References (30)

1. Agency for Healthcare Research and Quality Funding Announcements. http://www.ahrq.gov/fund/grantix.htm#RFA. Accessed January 28, 2010.
2. Department of Health and Human Services. Federal Coordinating Council for Comparative Effectiveness Research: report to the president and the congress. http://www.hhs.gov/recovery/programs/cer/cerannualrpt. pdf. Updated June 30, 2009. Accessed October 8, 2010.
3. Congressional Budget Office. Research on comparative effectiveness of medical treatment. issues and options for an expanded federal role. http://www.cbo.gov/ftpdocs/88xx/doc8891/Frontmatter.1.2.shtml. Updated December 2007. Accessed October 8, 2010.
4. Initial National Priorities on Comparative Effectiveness Research. Washington, DC: Institute of Medicine; 2009.
5. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624-1632. doi:10.101/jama.290.12.1624 PubMed (Pubitemid 37430387)
6. Rush AJ, Fava M, Wisniewski SR, et al.; STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142. doi:10.1016/S0197-2456(03)012-0 PubMed (Pubitemid 38230109)
7. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa05168 PubMed (Pubitemid 41345943)
8. Nierenberg AA, Sylvia LG, Leon AC, et al.; LiTMUS Study Group. Lithium Treatment-Moderate Dose Use Study (LiTMUS) for bipolar disorder: rationale and design. Clin Trials. 2009;6(6):637-648. doi:10.17/17407450934739 PubMed
9. Kraemer HC, Glick ID, Klein DF. Clinical trials design lessons from the CATIE study. Am J Psychiatry. 2009;166(11):1222-1228. doi:10.176/api.ajp.209. 08121809 PubMed
10. Piaggio G, Elbourne DR, Altman DG, et al. CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295(10):1152-1160. doi:10.101/jama.295.10.152 PubMed (Pubitemid 43352345)
11. Cook TD, DeMets DL. Introduction to Statistical Methods for Clinical Trials. Boca Raton, LA: Chapman & Hall/CRC; 2008.
12. Leon AC. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments. J Clin Psychiatry. 2004;65(11):1511-1514. doi:10.408/JCP.v65n1 PubMed
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
14. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825-835. PubMed
15. Cohen J. A power primer. Psychol Bull. 1992;112(1):155-159. doi:10.1037/03-2909.12.1.15 PubMed
16. Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? a meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429-447. doi:10.1038/sj.mp.402136 PubMed
17. Lehr R. Sixteen S-squared over D-squared: a relation for crude sample size estimates. Stat Med. 1992;11(8):1099-1102. doi:10.102/sim.47801081 PubMed
18. Leon AC, Davis LL. Enhancing clinical trial design of interventions for posttraumatic stress disorder. J Trauma Stress. 2009;22(6):603-611. PubMed
19. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research. Guidance for Industry: Non- Inferiority Clinical Trials (draft guidance). Rockville, MD: Food and Drug Administration; 2010. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM202140. pdf. Updated March 2010. Accessed October 8, 2010.
20. Pocock SJ. The pros and cons of noninferiority trials. Fundam Clin Pharmacol. 2003;17(4):483-490. doi:10.1046/j.1472-8206.203.0162.x PubMed (Pubitemid 36920651)
21. Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313(7048):36-39. PubMed (Pubitemid 26229889)
22. Julious SA. Sample sizes for clinical trials with normal data. Stat Med. 2004;23(12):1921-1986. doi:10.102/sim.1783 PubMed
23. ClinicalTrials.gov. A randomized, double-blind, placebo- and active- controlled, multicenter study to evaluate the efficacy, safety and tolerability of iloperidone in schizophrenic patients in acute exacerbation followed by a long-term treatment phase. http://clinicaltrials.gov/ct2/ show/NCT00254202. Accessed January 28, 2010.
24. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placeboand ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008; 28(suppl 1):S20-S28. doi:10.1097/JCP.0b013e318169d4ce PubMed (Pubitemid 351397673)
25. Vanda Pharmaceuticals announces receipt of not approvable letter From FDA for iloperidone. http://phx.corporate-ir.net/phoenix. zhtml?c=196233&p= irol-newsArticle&ID=1179851&highlight. Accessed January 9, 2010.
26. FDA approves Fanapt to treat schizophrenia http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm149578.htm. Accessed January 9, 2010.
27. Insel TR. Psychiatrists' relationships with pharmaceutical companies: part of the problem or part of the solution? JAMA. 2010;303(12):1192-1193. doi:10.101/jama.2010.317 PubMed
28. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments: part 1: ethical and scientific issues. Ann Intern Med. 2000;133(6):455-463. PubMed
29. The European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products. Note for Guidance on Clinical Investigations of Medicinal Products in the Treatment of Depression. http://www.tga.gov.au/ docs/pdf/euguide/ewp/ 051897en.pdf. Updated April 25, 2002. Accessed October 8, 2010.
30. The European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products. Note for Guidance on Clinical Investigations of Medicinal Products in the Treatment of Schizophrenia. http://www.tga.gov.au/ docs/pdf/euguide/ewp/055995en.pdf. Updated February 26, 1998. Accessed October 8, 2010.